Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Policy / Regulatory

CDE Reference Standards 101st Batch Seeks Public Feedback

Fineline Cube Dec 23, 2025
Company Drug

Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion

Fineline Cube Dec 23, 2025
Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Fineline Cube Dec 23, 2025
Company Deals

Dartsbio Licenses Potential First-in-Class BsAb DS005 to Duality Biologics

Fineline Cube Nov 3, 2022

China-based Dartsbio Pharmaceuticals, Ltd has announced a licensing deal with Duality Biologics, a novel modality...

Company Deals

Fosun Pharma Terminates Equity Transfer Deal with OncoCare Medical

Fineline Cube Nov 3, 2022

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the termination of...

Company Drug

Antengene’s CD73 Inhibitor ATG-037 Greenlit for Phase I Study by NMPA

Fineline Cube Nov 3, 2022

China-based Antengene Corporation Limited (HKG: 6996) has announced receiving approval from the National Medical Products...

Company Medical Device

Sino Medical Sciences’ Non-Compliant Balloon Catheter Approved by NMPA

Fineline Cube Nov 3, 2022

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving market approval from the...

Company Drug

Hengrui’s Pyrotinib Granted Breakthrough Therapy Designation by CDE

Fineline Cube Nov 3, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Hengrui Medicine Co., Ltd’s (SHA:...

Company Drug

NMPA Approves Humanwell’s Generic Clobazam for Lennox-Gastaut Syndrome

Fineline Cube Nov 3, 2022

China-based Yichang Humanwell Pharmaceutical Co., Ltd’s generic version (oral suspension) of Sanofi’s clobazam (trade name:...

Company Drug

NMPA Approves Luye Pharma’s LY03005 for Depression Treatment

Fineline Cube Nov 3, 2022

China-based Luye Pharma Group (HKG: 2186) has announced that its Category 1 chemical drug LY03005...

Company Drug Policy / Regulatory

Shanghai SMPA Suspends HEC’s Linagliptin Procurement Over Patent Infringement

Fineline Cube Nov 3, 2022

The Shanghai Sunshine Medical Procurement All-in-One (SMPA) platform has revealed that it has suspended the...

Company Drug

Shanghai Pharmaceuticals Gets NMPA Clearance for Sublingual Rasagiline

Fineline Cube Nov 3, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has announced receiving clinical clearance from the National Medical...

Company Deals

Baidu Health Partners with Shanghai Epiprobe for Cancer Early Screening

Fineline Cube Nov 3, 2022

China Internet giant Baidu’s Health Internet Hospital unit has announced a partnership with Shanghai Epiprobe...

Company Deals

Pharmaniaga Partners with JD.com to Enter China Market

Fineline Cube Nov 3, 2022

Malaysia-based pharma company Pharmaniaga Berhad (Pharmaniaga) is planning to bring its products into mainland China...

Company Drug

Eli Lilly’s Peresolimab and LOXO-783 Gain Tacit Clinical Trial Approvals in China

Fineline Cube Nov 2, 2022

The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approvals to...

Company Drug

Hua Medicine Launches Dorzagliatin, a First-in-Class Diabetes Drug, in China

Fineline Cube Nov 2, 2022

China-based Hua Medicine has announced the commercial launch of its Category 1 drug, dorzagliatin, with...

Company Medical Device

Yiming and Hexaell’s HepaCure Biocolumn Receives IND Approval for HBV-Induced Liver Failure

Fineline Cube Nov 2, 2022

China-based Yiming (Beijing) Cell Biotechnology Co., Ltd (also known as Ubrigene) and its partner Shanghai...

Company Drug

Yiming and Vitalgen’s Gene Therapy VGR-R01 Receives CDE Approval for Bietti Crystalline Dystrophy

Fineline Cube Nov 2, 2022

China-based Yiming (Beijing) Cell Biotechnology Co., Ltd (also known as Ubrigene) and its partner Shanghai...

Company Drug

LianBio’s TP-03 Begins Phase III Trial for Demodectic Blepharitis in China

Fineline Cube Nov 2, 2022

Shanghai-based biopharmaceutical company LianBio (OTCMKTS: LIANY) has announced the first patient dosing in a Phase...

Company Drug

Ascletis Files IND Application for COVID-19 Oral Inhibitor ASC11 with FDA

Fineline Cube Nov 2, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) has announced that the Investigational New Drug (IND) application...

Company Drug

RemeGen’s Telitacicept Shows Positive Results in Phase II Myasthenia Gravis Study

Fineline Cube Nov 2, 2022

China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has released data from a Phase II...

Company Deals

Immunochina Pharmaceuticals Raises Funds for Gene Therapy Development

Fineline Cube Nov 2, 2022

Beijing-based gene therapy specialist Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in...

Company Medical Device

BGI Genomics Receives NMPA Approval for Chromosome Aneuploidy Detection Kit

Fineline Cube Nov 2, 2022

China-based genomics firm BGI Genomics Co., Ltd (SHE: 300676), the Shenzhen-listed subsidiary of BGI Group,...

Posts pagination

1 … 542 543 544 … 601

Recent updates

  • Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion
  • Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections
  • Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal
  • 3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery
  • Gilead’s Seladelpar Wins China Hainan Approval for PBC Treatment
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk’s Wegovy Wins China Cardiovascular Approval in Weight-Loss Market Expansion

Company Drug

Aosaikang’s Delafloxacin Wins NMPA Approval as First Fluoroquinolone for China Infections

Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Company Drug

3SBio’s rhTPO Wins NMPA Approval for Liver Disease Thrombocytopenia Before Surgery

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.